Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults

Oladayo A. Oyebanji; Eleftherios Mylonakis; David H. Canaday

doi:10.1016/j.idc.2022.11.002

Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults

Oladayo A. Oyebanji, Eleftherios Mylonakis, David H. Canaday

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Institutionalized and community-dwelling older adults have been greatly impacted by the coronavirus disease 2019 (COVID-19) pandemic with increased morbidity and mortality. The advent of vaccines and their widespread use in this population has brought about a dramatic turnaround in COVID-19 outcomes. The immunogenicity and effectiveness of the various vaccine options worldwide are discussed. Optimization of vaccine usage will still be important to maximize protection due to reduced initial immunity, development of variant strains, and fading of immunity over time. There are also lessons learned specific to older populations for future pandemics of novel pathogens.

Original language	English (US)
Pages (from-to)	27-45
Number of pages	19
Journal	Infectious Disease Clinics of North America
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.idc.2022.11.002
State	Published - Mar 2023

Keywords

Aging
COVID-19 vaccine
Geriatric
Immunogenicity
Older adults
Vaccine effectiveness
SARS-CoV-2
Humans
COVID-19/prevention & control
Aged
Vaccines

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.idc.2022.11.002

Cite this

@article{71776a2e68c343f696449ad818c281de,

title = "Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults",

abstract = "Institutionalized and community-dwelling older adults have been greatly impacted by the coronavirus disease 2019 (COVID-19) pandemic with increased morbidity and mortality. The advent of vaccines and their widespread use in this population has brought about a dramatic turnaround in COVID-19 outcomes. The immunogenicity and effectiveness of the various vaccine options worldwide are discussed. Optimization of vaccine usage will still be important to maximize protection due to reduced initial immunity, development of variant strains, and fading of immunity over time. There are also lessons learned specific to older populations for future pandemics of novel pathogens.",

keywords = "Aging, COVID-19 vaccine, Geriatric, Immunogenicity, Older adults, Vaccine effectiveness, SARS-CoV-2, Humans, COVID-19/prevention & control, Aged, Vaccines",

author = "Oyebanji, {Oladayo A.} and Eleftherios Mylonakis and Canaday, {David H.}",

note = "Funding Information: This work was supported by NIH AI129709-03S1, U01 CA260539-01, and CDC 200-2016-91773.",

year = "2023",

month = mar,

doi = "10.1016/j.idc.2022.11.002",

language = "English (US)",

volume = "37",

pages = "27--45",

journal = "Infectious Disease Clinics of North America",

issn = "0891-5520",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults

AU - Oyebanji, Oladayo A.

AU - Mylonakis, Eleftherios

AU - Canaday, David H.

N1 - Funding Information: This work was supported by NIH AI129709-03S1, U01 CA260539-01, and CDC 200-2016-91773.

PY - 2023/3

Y1 - 2023/3

N2 - Institutionalized and community-dwelling older adults have been greatly impacted by the coronavirus disease 2019 (COVID-19) pandemic with increased morbidity and mortality. The advent of vaccines and their widespread use in this population has brought about a dramatic turnaround in COVID-19 outcomes. The immunogenicity and effectiveness of the various vaccine options worldwide are discussed. Optimization of vaccine usage will still be important to maximize protection due to reduced initial immunity, development of variant strains, and fading of immunity over time. There are also lessons learned specific to older populations for future pandemics of novel pathogens.

AB - Institutionalized and community-dwelling older adults have been greatly impacted by the coronavirus disease 2019 (COVID-19) pandemic with increased morbidity and mortality. The advent of vaccines and their widespread use in this population has brought about a dramatic turnaround in COVID-19 outcomes. The immunogenicity and effectiveness of the various vaccine options worldwide are discussed. Optimization of vaccine usage will still be important to maximize protection due to reduced initial immunity, development of variant strains, and fading of immunity over time. There are also lessons learned specific to older populations for future pandemics of novel pathogens.

KW - Aging

KW - COVID-19 vaccine

KW - Geriatric

KW - Immunogenicity

KW - Older adults

KW - Vaccine effectiveness

KW - SARS-CoV-2

KW - Humans

KW - COVID-19/prevention & control

KW - Aged

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85148075288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148075288&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2022.11.002

DO - 10.1016/j.idc.2022.11.002

M3 - Review article

C2 - 36805013

AN - SCOPUS:85148075288

SN - 0891-5520

VL - 37

SP - 27

EP - 45

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

IS - 1

ER -

Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this